NextBillion - An Initiative of the William Davidson Institute at the University of Michigan

Thursday, May 18, 2017

India’s big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.

The lengthy timeline is a concern not only in India but around the world, as India’s pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.

U.S. and European Union regulators have called on India’s $16 billion pharmaceutical industry to step up their efforts if it wants to continue to dominate the generic drugs sector.